5245582026-04-012026-06-305245582026-04-012026-06-30in-capmkt:OtherExpenses1Member5245582026-04-012026-06-30in-capmkt:OtherExpenses2Member5245582026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524558NEULANDLABNOTLISTEDINE794A01010NEULAND LABORATORIES LIMITEDMain BoardEquity2026-04-012027-03-312026-08-052026-07-20INRLakhsQuarterlyFirst quarterSingle segmentManufacturing of Active Pharmaceuticals2026-08-0510:00:002026-08-0515:42:00Declaration of unmodified opinionfalsefalseNot Applicable2026-04-012026-06-30UnauditedStandalone641577100084917000650068800022876920000-774540001030243000697190002656090009495210004525330000197535800001975358000508803000-706400050173900001473619000000014736190000147361900012900500010114.86114.8600114.86114.861. The financial results for the quarter ended June 30, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 05, 2026. <br /> <br /> 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br /> <br /> 3. The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". In accordance with Ind AS 108 - 'Operating segments', segment information has been given in the unaudited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in these unaudited standalone financial results. <br /> <br /> 4. The EPS for quarters has not been annualised. <br /> <br /> 5. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year March 31, 2026 and published unaudited figures upto nine months of the relevant financial year. Manufacturing expenses479357000Other expenses470164000000UnauditedtrueM S K A & Associates LLP, Chartered Accountantstrue2027-07-31